US Patent

US9592195 — Stable effervescent bisphosphonate formulations with rapid solubilization characteristics

Formulation · Assigned to EFFRX PHARMACEUTICALS SA · Expires 2031-12-05 · 6y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a stable effervescent formulation of a bisphosphonate, specifically alendronate sodium, that rapidly dissolves in water.

USPTO Abstract

A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring.

Drugs covered by this patent

Patent Metadata

Patent number
US9592195
Jurisdiction
US
Classification
Formulation
Expires
2031-12-05
Drug substance claim
No
Drug product claim
Yes
Assignee
EFFRX PHARMACEUTICALS SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.